Top: Univariate analysis | ||||
Factor | Parameter estimate | SE | 95% CI | P value |
Gender | ||||
Male | 0.440 | 0.256 | −0.062 to 0.942 | 0.0859 |
Female | Ref | |||
Race/ethnicity | ||||
Asian | 0.709 | 0.284 | 0.151 to 1.268 | 0.0129 |
Black/African-American | 0.660 | 0.175 | 0.316 to 1.003 | 0.0002 |
Hispanic/Latino | 0.600 | 0.203 | 0.201 to 0.999 | 0.0033 |
Other | 0.602 | 0.461 | −0.303 to 1.508 | 0.1920 |
White/Caucasian | Ref | |||
Age at visit | −0.025 | 0.005 | −0.035 to −0.015 | <0.0001 |
Age at diagnosis | −0.035 | 0.005 | −0.045 to −0.024 | <0.0001 |
Time since diagnosis | 0.011 | 0.008 | −0.005 to 0.027 | 0.1793 |
Low C3 and/or C4 | 0.648 | 0.149 | 0.356 to 0.940 | <0.0001 |
Elevated CB-CAPs | 0.958 | 0.145 | 0.672 to 1.244 | <0.0001 |
Anti-dsDNA positivity | 0.548 | 0.156 | 0.241 to 0.855 | 0.0005 |
Use of hydroxychloroquine | −0.221 | 0.180 | −0.575 to 0.134 | 0.2221 |
Use of corticosteroids | 0.641 | 0.158 | 0.330 to 0.952 | <0.0001 |
Use of immunosuppressants | 0.893 | 0.151 | 0.595 to 1.190 | <0.0001 |
CB-CAPs, cell-bound complement activation products; dsDNA, double-stranded DNA; LSI, Lupus Severity Index.